CHIRON GAINING 350-PERSON CIBA CORNING SALES FORCE FOR LAUNCH OF bDNA PROBES
This article was originally published in The Gray Sheet
Executive SummaryCHIRON GAINING 350-PERSON CIBA CORNING SALES FORCE FOR LAUNCH OF bDNA PROBES under development by Chiron. Chiron's acquisition of Ciba Corning Diagnostics (CCD), which will be effected as part of an agreement that will give Ciba-Geigy a 49.9% stake in Chiron, will provide Chiron with an established sales group and customer and distribution base for the commercial introduction of its Quantiplex branched DNA (bDNA) signal amplification technology diagnostics. CCD, which had sales of about $98 mil. in 1993, supplements its sales organization with a 300-person service group.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.